Exicure, Inc. (NASDAQ:XCUR) Sees Large Decrease in Short Interest

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a large decrease in short interest during the month of June. As of June 30th, there was short interest totaling 6,731 shares, a decrease of 54.4% from the June 15th total of 14,757 shares. Based on an average trading volume of 70,886 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.2% of the shares of the stock are short sold.

Exicure Stock Performance

Shares of Exicure stock opened at $1.62 on Thursday. Exicure has a 52-week low of $1.55 and a 52-week high of $9.50. The firm has a 50-day moving average of $2.60 and a 200-day moving average of $3.79. The stock has a market cap of $10.33 million, a PE ratio of -1.05 and a beta of 3.61.

Exicure (NASDAQ:XCUR) last issued its earnings results on Friday, May 29th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($18.60) by $18.31.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.